Why do quaternary AChE inhibitors like neostigmine produce mainly peripheral effects while physostigmine can also act centrally?
Choose an answer, then check it.
Clinical Pharmacology · Cholinergic Medications
Acetylcholinesterase Inhibitors
On this page 5 sections
In 30 seconds
Acetylcholinesterase (AChE) inhibitors don't stimulate cholinergic receptors directly — they block the enzyme that normally destroys acetylcholine (ACh), so ACh accumulates and keeps stimulating both muscarinic and nicotinic receptors. This "indirect agonism" treats weak muscles (myasthenia gravis), a sluggish gut or bladder, certain glaucoma, anesthesia-related paralysis, and dementia-related memory loss — but because the same enzyme sits in nearly every cholinergic synapse, overdose produces a predictable, total-body cholinergic flood.
The college version
The core mechanism
Acetylcholinesterase sits in the synaptic cleft and rapidly hydrolyzes ACh into choline and acetate, terminating the signal almost instantly. When an inhibitor occupies or destroys this enzyme, ACh released by the presynaptic neuron is no longer cleared away — it accumulates and keeps binding muscarinic receptors (glands, smooth muscle, heart) and nicotinic receptors (neuromuscular junction, autonomic ganglia) far longer than normal. The drug doesn't touch the receptor itself; it amplifies the body's own neurotransmitter, which is why these are called "indirect-acting" agents, in contrast to direct agonists like bethanechol.
Three categories
Reversible inhibitors bind the enzyme's active site temporarily via a carbamate linkage that eventually hydrolyzes off. Neostigmine and pyridostigmine are quaternary ammonium compounds — permanently charged, so they cannot cross the blood-brain barrier. Their effects stay peripheral: skeletal muscle strengthening, GI/bladder stimulation, and cardiac/pupillary effects. Edrophonium binds even more briefly and is used diagnostically to unmask myasthenic weakness. Physostigmine is a tertiary amine, uncharged enough to cross the blood-brain barrier, making it useful for central anticholinergic toxicity but more prone to central side effects.
Centrally acting reversible inhibitors — donepezil, rivastigmine, galantamine — are tertiary, lipid-soluble compounds engineered to penetrate the CNS preferentially. Raising ACh in the hippocampus and cortex modestly slows Alzheimer-related cognitive decline without altering the underlying disease. This class is covered in depth in a later Alzheimer-focused subject; here it mainly illustrates how molecular charge determines CNS access.
Irreversible inhibitors — organophosphates — phosphorylate the enzyme's active site in a bond resistant to hydrolysis, permanently disabling that molecule; recovery requires synthesizing entirely new enzyme, which can take weeks. Organophosphates include some insecticides and nerve agents; their poisoning and antidotes are covered in a dedicated sibling topic.
Clinical uses
In myasthenia gravis, autoantibodies destroy nicotinic receptors at the neuromuscular junction; pyridostigmine raises ACh enough to compete more effectively for remaining receptors, improving strength. Reversal of nondepolarizing neuromuscular blockade uses neostigmine to outcompete agents like rocuronium at the NMJ, always paired with an antimuscarinic (e.g., glycopyrrolate) to blunt resulting bradycardia and secretions. Postoperative ileus and urinary retention respond to neostigmine's muscarinic smooth-muscle stimulation, promoting peristalsis and bladder contraction. In glaucoma, older agents increase aqueous outflow by contracting the ciliary muscle. Anticholinergic toxicity can be reversed with physostigmine specifically because it crosses into the CNS to restore central cholinergic tone.
Cholinergic crisis vs. myasthenic crisis
Both present with severe weakness, making them dangerous to distinguish. A myasthenic crisis is undertreatment and improves with more AChE inhibitor. A cholinergic crisis is overtreatment — excess ACh causes nicotinic desensitization and depolarizing blockade at the NMJ, paralyzing muscle — and worsens with more drug. Cholinergic crisis is distinguished by accompanying muscarinic signs (excess secretions, bradycardia, GI cramping); the edrophonium test can help differentiate them, used cautiously given its own risks.
Adverse effects
Because these drugs amplify ACh everywhere, toxicity follows the muscarinic pattern remembered as SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) or DUMBELS (Defecation, Urination, Miosis, Bradycardia/Bronchospasm, Emesis, Lacrimation, Salivation). Bradycardia and bronchospasm are the most dangerous features, especially with pre-existing cardiac or pulmonary disease. Nicotinic excess can cause fasciculations progressing to weakness. Atropine counteracts muscarinic symptoms of overdose but has no effect on nicotinic/neuromuscular weakness.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine texts that keep flashing on screen unless someone deletes them right away. Acetylcholine is the message, and acetylcholinesterase is the delete button. AChE inhibitor drugs jam that delete button, so the message — move the muscle, slow the heart, make more spit — keeps flashing instead of vanishing after one read.
Some of these drugs only jam the button in your body, not your brain, because they carry a permanent electric charge that can't sneak past the brain's security gate (the blood-brain barrier). Other drugs are neutral enough to slip through, jamming the button inside the brain too — that's how some memory medicines work.
A little jamming helps someone whose muscles are too weak, letting their few working "on" switches get used again and again. But jamming too hard floods the whole body with messages at once — drooling, watery eyes, a slow heartbeat, tight airways, and muscles that stop responding because they're overwhelmed, not understimulated. Too little drug and a weak person stays weak; too much and the signal turns into a jam that shuts muscles down anyway.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with myasthenia gravis on pyridostigmine develops worsening generalized weakness. What additional finding would point toward cholinergic crisis rather than myasthenic crisis, and why?
Show answer
Accompanying muscarinic signs — excess salivation, tearing, GI cramping, or a slowed heart rate — alongside the weakness suggest cholinergic crisis, because that pattern reflects too much acetylcholine overall rather than too little coverage of the receptor deficit.
Why is an AChE inhibitor described as an "indirect" cholinergic agent rather than a direct agonist, in terms of what it actually binds?
Show answer
An AChE inhibitor binds and blocks the enzyme that breaks down acetylcholine, not the cholinergic receptor itself; it raises the amount of the body's own transmitter available to act on muscarinic and nicotinic receptors, rather than mimicking that transmitter directly at the receptor.
Quick check
3 questions here. Answers stay hidden until you check.
Why is neostigmine co-administered with an antimuscarinic agent when reversing nondepolarizing neuromuscular blockade?
Choose an answer, then check it.
What is the fundamental difference between irreversible (organophosphate) and reversible AChE inhibitors?
Choose an answer, then check it.
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.